Anti-platelet Therapy in the Primary Prevention of Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease. - Antiplatelet therapy in COPD (APPLE-COPD:ICON 2)

The Newcastle upon Tyne Hospitals NHS Foundation Trust0 个研究点目标入组 120 人开始时间: 2015年5月5日最近更新: 2019年6月30日

试验速览

暂无简介。

•1)Abnormal spirometry with FEV1<80% and FEV1/FVC ratio <70% of predicted
•2)Smoking history that is 10-pack years or greater (current or ex smokers can be included)
•3)Patient has the capacity to consent
•4)18 years or over
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 200
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 40

•1)Any condition that is being concurrently treated through anticoagulation or antiplatelet therapy (atrial fibrillation, deep vein thrombosis, valve prosthesis, recent myocardial infarction, use of drug eluting stents)
•2)Other specific contraindications to management with antiplatelet medication (bleeding risks, allergies)
•3)Any contraindication for Aspirin and Ticagrelor use
•4)Other concurrent terminal illnesses with life expectancy less than 1 year (congestive cardiac failure, carcinoma etc.)
•5)Current involvement in another clinical trial or exposure to another IMP within the previous 30 days
•6)COPD with an atypical cause (e.g. A1- antitrypsin deficiency)
•7)Planned/ Expected major surgery where anti-platelet therapy would be ceased
•8)Pregnancy, planned pregnancy or current breast-feeding
•9)Patient is unable to provide informed consent
•10)Younger than 18 years

发起方